Log In
C&EN congratulates Dan Fagin on winning the 2014 Pulitzer Prize in General Nonfiction for “Toms River: A Story of Science and Salvation” (Bantam Books). C&EN’s Rudy Baum reviewed “Toms River” last May.
Copyright © 2006 American Chemical Society
June 19, 2006 Cover
Volume 84, Issue 25
Volume 84, Issue 25
PHARMA'SROAD AHEAD
C&EN examines how the pharmaceutical industry, now on the defensive, is trying to win back the public's confidence and enhance productivity
Credit: Photodisc
» Full Article
June 19, 2006 Issue
Volume 84, Issue 25
June 19, 2006 Issue, Vol. 84 | Iss. 25
C&EN examines how the pharmaceutical industry, now on the defensive, is trying to win back the public's confidence and enhance productivity
(pp. 24-28)
Features
Science & Technology
Asymmetric reaction constructs three new C-C bonds and four stereocenters (p.13)
Business
Fundamental changes erupt across the industry as companies strive to improve drug efficacy and safety and R&D efficiency in the face of negative public opinion (pp. 30-55)
News of the Week
Triple Cascade
Asymmetric reaction constructs three new C-C bonds and four stereocenters
(p.13)Georgia Gulf Will Buy Royal Group
Deal will create a large, back-integrated vinyl products supplier
(p.14)Greener Cleaners
EPA initiative urging phaseout of NPE surfactants receives mixed reviews
(p.14)Aging Cells Get New Lease On Life
Small molecule is found to extend lifetime of mammalian cells
(p.15)Schering Shares
Merck's threat to derail Bayer's acquisition of Schering is resolved
(p.15)Herzenberg Nabs Kyoto Prize
Award honors the developer of the fluorescence-activated cell sorter
(p.16)Departments
Business
Researchers Are Admonished To Stay Focused
(pp. 42-43)
Many Doubt The $800 Million Pharmaceutical Price Tag
(p.50)
Fundamental changes erupt across the industry as companies strive to improve drug efficacy and safety and R&D efficiency in the face of negative public opinion
(pp. 30-55)
C&EN examines how the pharmaceutical industry, now on the defensive, is trying to win back the public's confidence and enhance productivity
(pp. 24-28)
Government & Policy
For Most Retirees, Medicare Program Fails To Lower Costs
(pp. 84-85)
Citing Application Backlog, Makers Of Generic Drugs Seek To Boost FDA Funding
(p.92)
Strong action on drug safety and pricing is more likely to come from states than from Congress or FDA
(pp. 80-99)
FDA Process Guidelines Encourage Efficient Plant Controls
(p.66)
Science & Technology
To eliminate R&D bottlenecks, drug companies are evaluating all phases of discovery and development and are using novel approaches to speed them up
(pp. 56-78)Editor's Page
Most popular
Viewed
Commented
Chemistry Job Listings